# Long-Acting Injectable Pharmaceuticals Market Size, Share & Growth

> The Global Long-Acting Injectable Pharmaceuticals market was valued at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035, growing at a 10.76% CAGR, according to Vectomat Insights. North America leads with 39.0% of revenue, microspheres are the largest product type at 32.0%, and implants grow fastest at 15.1% a year.

- Publisher: Vectomat Insights
- Report code: VMI-1-1-27807
- Published: 2026-11-19
- Canonical URL: https://www.vectomatinsights.com/report/long-acting-injectable-pharmaceuticals-market
- Base year 2025: USD 12,642.7 Mn
- Forecast 2035: USD 35,129.3 Mn
- CAGR 2026–2035: 10.76%

## Key insights

- The market is projected to grow from USD 12,642.7 Mn in 2025 to USD 35,129.3 Mn by 2035 at a 10.76% CAGR, according to Vectomat Insights.
- Microspheres are the dominant product type at 32.0% of 2025 revenue (USD 4,045.7 Mn).
- Implants are the fastest-growing product type, forecast to compound at 15.1% a year to USD 11,348.3 Mn by 2035.
- Psychiatric disorders are the dominant therapeutic area at 33.7% of revenue, because depots address the missed-dose problem behind most schizophrenia relapse.
- Hospitals are the dominant end user at 43.7% of 2025 revenue, since most initiation doses and implant insertions need trained staff.
- North America leads regionally with a 39.0% share (USD 4,930.7 Mn); the U.S. alone accounts for USD 3,944.6 Mn.
- Asia Pacific is the fastest-growing region, with South Korea expanding at a 13.0% CAGR and Japan at 11.1%.
- Platform licensing is reshaping competition: Medincell's copolymer depot sits behind Teva's 2026 WELTRUZA approval and Camurus has licensed FluidCrystal to Eli Lilly.
- PLGA-based formulations are forecast to lift their share from 47.4% to 62.7% of revenue by 2035 as monthly and longer metabolic depots reach the market.

## Figures

![Long-acting injectables market size — USD 12,642.7 Mn (2025) to USD 35,129.3 Mn (2035) at 10.76% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-size-vmi.png) — The Global Long-Acting Injectable Pharmaceuticals market grows from USD 12,642.7 Mn in 2025 to USD 35,129.3 Mn by 2035, a 10.76% CAGR. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals market drivers, restraints, opportunities and challenges | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-droc-vmi.png) — Adherence gaps, twice-yearly HIV prevention and longer dosing intervals drive the market, while premium pricing and complex microsphere manufacturing restrain it. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals market share by region — North America leads with 39.0% in 2025 | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-regional-share-vmi.png) — North America leads the Global Long-Acting Injectable Pharmaceuticals market with a 39.0% share in 2025, while Asia Pacific grows fastest. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-acting injectables market segmentation — product type, therapeutic area, technology, end user | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-segments-vmi.png) — Microspheres, psychiatric disorders, PLGA-based technology and hospitals lead their respective dimensions in 2025. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals market share by product type — Microspheres 32.0% in 2025 | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-product-type-share-vmi.png) — Microspheres lead the product type split of the Long-Acting Injectable Pharmaceuticals market with a 32.0% share in 2025. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals market share by end user — Hospitals 43.7% in 2025 | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-end-user-share-vmi.png) — Hospitals lead the end-user split of the Long-Acting Injectable Pharmaceuticals market with a 43.7% share in 2025. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-acting injectables market product type mix by region — North America, Europe, Asia Pacific | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-regional-segments-vmi.png) — Microspheres lead the product mix in North America and Europe, while suspensions carry a larger share in Asia Pacific. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals competitive landscape — positioning of 9 leading companies | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-competitive-landscape-vmi.png) — Johnson & Johnson, Gilead Sciences, ViiV Healthcare and Pfizer lead on scale, while Organon and Gilead set the pace on dosing interval. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Long-Acting Injectable Pharmaceuticals market at a glance — USD 12,642.7 Mn (2025), 10.76% CAGR | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-key-numbers-vmi.png) — Key numbers for the Global Long-Acting Injectable Pharmaceuticals market: size, growth, leading segments, regions and companies. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![United States long-acting injectables market — USD 3,944.6 Mn (2025) to USD 9,865.3 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-united-states-snapshot-vmi.png) — The United States long-acting injectable pharmaceuticals market grows from USD 3,944.6 Mn in 2025 to USD 9,865.3 Mn by 2035 at a 9.6% CAGR. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Germany long-acting injectable pharmaceuticals market — USD 955.8 Mn (2025) to USD 2,304.6 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-germany-snapshot-vmi.png) — The Germany long-acting injectable pharmaceuticals market grows from USD 955.8 Mn in 2025 to USD 2,304.6 Mn by 2035 at a 9.2% CAGR. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.
![Japan long-acting injectable pharmaceuticals market — USD 814.2 Mn (2025) to USD 2,332.8 Mn (2035) | Vectomat Insights](https://vectomat-media-prod.tor1.cdn.digitaloceanspaces.com/reports/long-acting-injectable-pharmaceuticals-market/5011cd4fbb4f8477/long-acting-injectable-pharmaceuticals-market-japan-snapshot-vmi.png) — The Japan long-acting injectable pharmaceuticals market grows from USD 814.2 Mn in 2025 to USD 2,332.8 Mn by 2035 at a 11.1% CAGR. Source: Vectomat Insights, Long-Acting Injectable Pharmaceuticals Market Report.

## Market size (USD million)

| Year | Value |
|---|---|
| 2023 | 9,981.4 |
| 2024 | 11,037.8 |
| 2025 | 12,642.7 |

## Share by Product Type (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Microspheres | 32% | 4,045.7 |
| In-Situ Forming Depots/Gels | 26% | 3,287.1 |
| Implants | 22% | 2,781.4 |
| Suspensions | 20% | 2,528.5 |

## Share by Therapeutic Area (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Psychiatric Disorders | 33.7% | 4,258.4 |
| Contraception | 26.3% | 3,327.2 |
| Oncology | 18% | 2,275.7 |
| Infectious Disease | 14% | 1,770.0 |
| Ophthalmology, endocrinology and metabolic disease | 8% | 1,011.4 |

## Share by Technology (2025)

| Segment | Share | USD Mn |
|---|---|---|
| PLGA-Based | 47.4% | 5,987.8 |
| Non-PLGA Polymer-Based | 26.6% | 3,367.8 |
| Non-Polymeric (Implant) | 16% | 2,022.8 |
| Oil-based depot and crystal suspension technologies | 10% | 1,264.3 |

## Share by End User (2025)

| Segment | Share | USD Mn |
|---|---|---|
| Hospitals | 43.7% | 5,522.6 |
| Specialty Pharmacies | 30% | 3,792.8 |
| Homecare Settings | 16.2% | 2,047.6 |
| Correctional & Public Health Facilities | 10.1% | 1,279.7 |

## Regional share

| Region | Share | USD Mn |
|---|---|---|
| North America | 39% | 4,930.7 |
| Europe | 27% | 3,413.5 |
| Asia Pacific | 23% | 2,907.8 |
| Latin America | 5% | 632.1 |
| The Middle East | 3.1% | 386.0 |
| Africa | 2.9% | 372.6 |

## Key companies

- Johnson & Johnson (U.S.): Paliperidone palmitate antipsychotic depots (Invega Sustenna, Trinza, Hafyera)
- Otsuka Pharmaceutical (Japan): Aripiprazole depots with Lundbeck (Abilify Maintena, Abilify Asimtufii)
- Teva Pharmaceuticals (Israel): Subcutaneous antipsychotic depots (Uzedy, WELTRUZA)
- Gilead Sciences (U.S.): Twice-yearly lenacapavir for HIV prevention (Yeztugo, Yeytuo)
- ViiV Healthcare (U.K.): Long-acting cabotegravir regimens (Cabenuva, Apretude)
- Pfizer (U.S.): DMPA contraceptive injections (Depo-Provera, Sayana Press) and monthly GLP-1 development
- Organon (U.S.): Contraceptive implant NEXPLANON
- Alkermes (Ireland): Aristada aripiprazole lauroxil and Vivitrol naltrexone microspheres
- Indivior (U.S.): Monthly buprenorphine depot Sublocade for opioid use disorder
- Ipsen (France): Somatuline lanreotide and Decapeptyl triptorelin depots
- Camurus (Sweden): FluidCrystal lipid depots (Brixadi/Buvidal, Oczyesa)
- Medincell (France): BEPO copolymer subcutaneous depot technology
- Foresee Pharmaceuticals (Taiwan): Ready-to-use leuprolide mesylate depots (CAMCEVI)
- Lupin (India): PrecisionSphere microsphere platform and complex long-acting generics

## FAQs

### How big is the Long-Acting Injectable Pharmaceuticals market in 2025?

The Global Long-Acting Injectable Pharmaceuticals market stood at USD 12,642.7 Mn in 2025 and is projected to reach USD 35,129.3 Mn by 2035 at a 10.76% CAGR. Psychiatric disorders account for the largest therapeutic share at 33.7%, followed by contraception at 26.3% and oncology at 18.0%, according to Vectomat Insights.

### Which product type grows fastest in long-acting injectables?

Implants are the fastest-growing product type, forecast to compound at 15.1% a year from USD 2,781.4 Mn in 2025 to USD 11,348.3 Mn by 2035. Longer labels such as Organon's five-year NEXPLANON approval in January 2026 and sustained-release ocular and hormone implants drive the gain, while microspheres remain the largest type at 32.0%, according to Vectomat Insights.

### Why do PLGA-based formulations dominate the technology split?

PLGA-based formulations held 47.4% of 2025 revenue because the polymer degrades predictably, letting developers tune release from one to six months, and regulators have reviewed PLGA depots since 1989. The segment is forecast to grow at 13.91% a year to USD 22,022.8 Mn by 2035, reaching 62.7% of the market. Lupin's PrecisionSphere program is adding partner capacity, according to Vectomat Insights.

### What is restraining long-acting injectable adoption?

Three factors slow adoption: premium pricing, with Yeztugo listed at about USD 28,000 a year in the U.S.; complex aseptic microsphere manufacturing that limits capacity and generic entry; and provider-administration and REMS requirements, which keep homecare growth to 3.65% a year, the slowest end-user rate. Generic erosion of older depots adds price pressure, according to Vectomat Insights.

### Which end user leads the long-acting injectables market?

Hospitals lead with 43.7% of 2025 revenue (USD 5,522.6 Mn) and are also the fastest-growing end user at 13.54% a year, because initiation doses, implant insertions and provider-administered HIV prevention need trained staff and observation space. Specialty pharmacies follow at 30.0%. Homecare settings hold 16.2% and correctional and public health facilities 10.1%, according to Vectomat Insights.

### What research methodology does the VMI Long-Acting Injectable Pharmaceuticals report use?

VMI combines a bottom-up model built from product-level revenue for branded depots, implants and suspensions with a top-down check against reported company franchise sales. Interviews with formulation scientists, pharmacists and public-sector buyers test the assumptions, and segment, regional and country values are reconciled to the USD 12,642.7 Mn base-year total. Country values are checked against regional totals, according to Vectomat Insights.

### Which companies are expanding long-acting platforms through partnerships?

Medincell licenses its copolymer depot to Teva, which won FDA approval for WELTRUZA in October 2026; Camurus signed a FluidCrystal incretin deal with Eli Lilly in June 2025; and Lupin opened its PrecisionSphere microsphere platform to partners in October 2025. Gilead has also signed access deals with the Global Fund, PEPFAR and PAHO. These deals trade price for reach, according to Vectomat Insights.

Cite as: Vectomat Insights (2026). Long-Acting Injectable Pharmaceuticals Market Report. https://www.vectomatinsights.com/report/long-acting-injectable-pharmaceuticals-market